Reborn Redx Inks Global Licensing Deal With AstraZeneca
AZ Buys Rights To Porcupine Inhibitor For Fibrotic Diseases
Executive Summary
AstraZeneca will take Redx's RXC006 into clinical development, targeting fibrotic diseases, giving valuable credibility to the biotech’s Wnt pathway hypothesis.
You may also be interested in...
Keen On NASDAQ Slot, Concentra Looks To Scupper Jounce And Redx Merger
In February, Jounce’s future looked bleak after the failure of vopratelimab and fears that its finances would run out. Now, it has two suitors with Concentra making a bid to compete with an all-stock merger with the UK’s Redx.
Redx Joins Forces With Jounce To Form $425m Cancer And Fibrosis Company
After a rollercoaster of a journey to date, UK firm Redx unveiled plans to merge with US biotech Jounce in a deal that would create a $425m transatlantic company with a robust cash runway through to 2025.
UK's Redx Rises On Stock Sale
A few months after bringing AstraZeneca onboard as a partner, the turnaround at the Alderley Park-based firm is moving ahead, buoyed by a fresh financing.